Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

by admin
RAD 202 receives approval to start Phase 1 therapeutic trial

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

Related Posts

Trump Threatens to Double Tariffs on Canadian Steel...

March 13, 2025

Reserve and Resource Update

May 20, 2025

Top 10 Aluminum-producing Countries

February 19, 2025

Grant Williams: Market Turbulence Ahead, but Resource Space...

January 30, 2025

Tuttle Capital Files for ETF Tied to UFO-Related...

February 19, 2025

Green River Gold Corp. Announces an Expansion into...

January 25, 2025

March Quarterly Appendix 4C

April 30, 2025

Opawica Explorations Inc Begins Field Work in Preparation...

December 20, 2024

US Capital Global Facilitates $50MM Financing to Accelerate...

June 7, 2025

Top 10 Copper Producers by Country

February 26, 2025